Page last updated: 2024-08-24
nelfinavir and tak 779
nelfinavir has been researched along with tak 779 in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Fukushima, D; Hisaichi, K; Jenkinson, S; Kazmierski, WM; Maeda, K; Matsunaga, N; Minamoto, C; Mitsuya, H; Nakai, H; Nishiyama, T; Nishizawa, R; Sagawa, K; Shibayama, S; Tada, H; Takaoka, Y | 1 |
| Fukushima, D; Hisaichi, K; Maeda, K; Minamoto, C; Mitsuya, H; Murota, M; Nakai, H; Nishiyama, T; Nishizawa, R; Sagawa, K; Shibayama, S; Tada, H; Takaoka, Y | 1 |
Other Studies
2 other study(ies) available for nelfinavir and tak 779
| Article | Year |
|---|---|
Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.
Topics: Administration, Oral; Animals; Anti-HIV Agents; CCR5 Receptor Antagonists; Cell Line, Tumor; Diketopiperazines; Drug Evaluation, Preclinical; HIV Core Protein p24; HIV-1; Humans; Microsomes, Liver; Rats; Receptors, CCR5; Spiro Compounds; Stereoisomerism | 2011 |
Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Benzoates; CCR5 Receptor Antagonists; Diketopiperazines; Dogs; Drug Evaluation, Preclinical; Guinea Pigs; Haplorhini; Humans; Rabbits; Rats; Receptors, CCR5; Structure-Activity Relationship | 2011 |